Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR1 | P21453 | 18/20 | 0.51 |
| ▸ | S1PR5 | Q9H228 | 15/20 | 0.51 |
| ▸ | S1PR4 | O95977 | 10/20 | 0.51 |
| ▸ | S1PR3 | Q99500 | 8/20 | 0.51 |
| ▸ | PRKX | P51817 | 1/20 | 0.40 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10088716 | 0.94 | S1PR1 (0.52) | S1PR1S1PR5S1PR4S1PR3PRKX | |
| SCHEMBL10088706 | 0.88 | S1PR5 (0.54) | S1PR1S1PR5S1PR4S1PR3PRKX | |
| SCHEMBL10088726 | 0.88 | S1PR1 (0.46) | S1PR1S1PR5S1PR4S1PR3PRKX | |
| SCHEMBL10088717 | 0.87 | S1PR5 (0.54) | S1PR1S1PR5S1PR4S1PR3PRKX | |
| SCHEMBL10088725 | 0.86 | S1PR1 (0.51) | S1PR1S1PR5S1PR4S1PR3PRKX | |
| SCHEMBL10088721 | 0.85 | S1PR1 (0.52) | S1PR1S1PR5S1PR4S1PR3PRKX | |
| SCHEMBL10089000 | 0.85 | S1PR1 (0.71) | S1PR1S1PR5S1PR4S1PR3PRKX | |
| SCHEMBL10088729 | 0.85 | S1PR1 (0.46) | S1PR1S1PR5S1PR4S1PR3PRKX | |
| SCHEMBL10089062 | 0.85 | S1PR5 (0.51) | S1PR1S1PR5S1PR4S1PR3PRKX | |
| SCHEMBL10088715 | 0.85 | S1PR5 (0.51) | S1PR1S1PR5S1PR4S1PR3PRKX |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2354134-B1 | 2H-CHROMENE DERIVATIVES AS STIMULATORS OF SPHINGOSINE 1-PHOSPHATE RECEPTOR | ASTELLAS PHARMA INC (JP) | 2016-02-24 | — | — | EP | disclosed |
| US-20120178735-A1 | 2H-CHROMENE COMPOUND AND DERIVATIVE THEREOF | ASTELLAS PHARMA INC. (JP) | 2012-07-12 | — | — | US | disclosed |
| US-20120178735-A1 | 2H-CHROMENE COMPOUND AND DERIVATIVE THEREOF | ASTELLAS PHARMA INC. (JP) | 2012-07-12 | — | — | US | disclosed |
| US-8193378-B2 | 2H-chromene compound and derivative thereof | ASTELLAS PHARMA INC. (JP) | 2012-06-05 | — | — | US | disclosed |
| US-8193378-B2 | 2H-chromene compound and derivative thereof | ASTELLAS PHARMA INC. (JP) | 2012-06-05 | — | — | US | disclosed |
| US-20110230463-A1 | 2H-CHROMENE COMPOUND AND DERIVATIVE THEREOF | ASTELLAS PHARMA INC. (JP) | 2011-09-22 | — | — | US | disclosed |
| US-20110230463-A1 | 2H-CHROMENE COMPOUND AND DERIVATIVE THEREOF | ASTELLAS PHARMA INC. (JP) | 2011-09-22 | — | — | US | disclosed |
| EP-2354134-A1 | 2H-CHROMENE COMPOUND AND DERIVATIVE THEREOF | Astellas Pharma Inc. (JP) | 2011-08-10 | — | — | EP | disclosed |
| WO-2010064707-A1 | 2H-CHROMENE COMPOUND AND DERIVATIVE THEREOF | アステラス製薬株式会社 (JP) | 2010-06-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110230463-A1 | 2H-CHROMENE COMPOUND AND DERIVATIVE THEREOF | S1PR1, S1PR2, CCR1 | S1PR1 1/4885S1PR5 4/4885S1PR4 5/4885 |
| US-20120178735-A1 | 2H-CHROMENE COMPOUND AND DERIVATIVE THEREOF | S1PR1, S1PR2, S1PR4 | S1PR1 1/4885S1PR5 7/4885S1PR4 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.